STOCKHOLDERS' EQUITY

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY

Stock Issuances

When the Company completes a business combination or asset acquisition, which are further described in Note 18, the Company may issue shares of the Company's common stock. Stock issuances in relation to acquisitions during the years ended December 31, 2022, 2021 and 2020 were as follows:

(In millions)	Period of Acquisition	Shares Issued	Fair Value of Shares Issued
OmicEra	May 2022	0.3	$	14.8
PreventionGenetics	December 2021	1.1	84.2
Ashion	April 2021	0.1	16.2
Thrive	January 2021	9.3	1,190.0
Targeted Digital Sequencing (“TARDIS”) license	January 2021	0.2	27.3
Paradigm Diagnostics, Inc. (“Paradigm”) and Viomics, Inc. (“Viomics”)	March 2020	0.4	28.8

Registered Direct Offering

In October 2020, the Company entered into securities purchase agreements with a limited number of institutional investors for the registered direct offering of 8.6 million shares of common stock at a price of $101.00 per share. The Company received, in the aggregate, approximately $861.7 million of net proceeds from the offering, after deducting $7.5 million for the offering expenses and other stock issuance costs paid by the Company.

Changes in Accumulated Other Comprehensive Loss

The amount recognized in AOCI for the years ended December 31, 2022, 2021 and 2020 were as follows:

(In thousands)	Cumulative Translation Adjustment		Unrealized Gain (Loss) on Securities		Accumulated Other Comprehensive Income (Loss)
Balance at January 1, 2020	$	(25)	$	(75)	$	(100)
Other comprehensive income before reclassifications	—		771		771
Amounts reclassified from accumulated other comprehensive loss	25		—		25
Net current period change in accumulated other comprehensive loss	25		771		796
Income tax expense related to items of other comprehensive loss	—		(170)		(170)
Balance at December 31, 2020	$	—	$	526	$	526
Other comprehensive income (loss) before reclassifications	23		(1,648)		(1,625)
Amounts reclassified from accumulated other comprehensive loss	—		(514)		(514)
Net current period change in accumulated other comprehensive loss	23		(2,162)		(2,139)
Income tax benefit related to items of other comprehensive loss	—		170		170
Balance at December 31, 2021	$	23	$	(1,466)	$	(1,443)
Other comprehensive income (loss) before reclassifications	30		(4,049)		(4,019)
Amounts reclassified from accumulated other comprehensive loss	—		226		226
Net current period change in accumulated other comprehensive loss	30		(3,823)		(3,793)
Balance at December 31, 2022	$	53	$	(5,289)	$	(5,236)

_________________________________

(1)There was no tax impact from the amounts recognized in AOCI for the year ended December 31, 2022.

Amounts reclassified from AOCI for the years ended December 31, 2022, 2021 and 2020 were as follows:

		Year Ended December 31,
Details about AOCI Components (In thousands)	Affected Line Item in the Statements of Operations	2022		2021		2020
Change in value of available-for-sale investments
Sales and maturities of available-for-sale investments	Investment income	$	226	$	(514)	$	—
Foreign currency adjustment	General and administrative	—		—		25
Total reclassifications		$	226	$	(514)	$	25